NATR

Business Context and Reporting Period

Company: Nature's Sunshine Products, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2003
Business Overview: The Company manufactures and distributes health and wellness products through a direct sales network of independent Distributors and Managers. Operations are segmented geographically into the United States, Latin America, Asia Pacific, and Other international markets.

Key Financial Metrics

Margins (9 Months 2003):
- Gross Margin (Sales less COGS): ~82.1%
- Operating Margin: 1.8%
- Net Profit Margin: 1.0%

Material Changes vs. Prior Period

• Revenue Decline: Sales revenue decreased 0.9% for the quarter and 4.0% for the nine-month period compared to 2002. The decline was driven by lower sales in the United States (down 6.7% QoQ) and international operations (down 6.4% for the nine months).
• Profitability Shift: The Company reported a net loss of $564,000 for the quarter, a significant reversal from the $3.478 million net income in the same period in 2002. Operating income turned negative for the quarter due to increased expenses.
• Expense Increases: Selling, General, and Administrative (SG&A) expenses increased 16.7% for the quarter, primarily due to $910,000 in severance costs associated with the termination of 49 employees and the realignment of management positions.
• Segment Performance:
  • Latin America: Sales declined 11.7% (9 months) due to the devaluation of the Venezuelan Bolivar and Brazilian import restrictions.
  • Asia Pacific: Sales declined 22.3% (9 months) due to competition in South Korea, though the quarter showed an 8.0% increase driven by the Synergy division and Thailand expansion.
  • Other Markets: Sales increased 29.9% (9 months), driven by growth in the Russian Federation, Israel, and the United Kingdom.

Guidance, Outlook, and Risks

• Cost Reduction: Management expects SG&A expenses to decrease as a percent of sales for the remainder of 2003. Cuts of approximately $7.0 to $9.0 million are expected to be realized over the remainder of 2003 and 2004.
• Volume Incentives: The Company is evaluating the accounting treatment of volume incentives. If reclassified as a deduction from gross revenue (per EITF 01-09) rather than an operating expense, reported revenue and expenses would decrease by equal amounts, with no impact on net income.
• Product Liability Risk: The Company faces inherent risks regarding product liability claims, particularly for products containing ephedrine alkaloids and kava, for which it cannot obtain standard insurance. A captive insurance company was established in June 2003 to cover these risks, but there is no assurance that accrued liabilities will be sufficient.
• SEC Review: The SEC staff has reviewed the Company's 2002 10-K and requested clarification on the accounting policy for volume incentives. Discussions are ongoing.
• Liquidity: The Company maintains a $15 million line of credit with $10 million outstanding as of September 30, 2003. Management believes working capital needs can be met through cash, operating activities, and the line of credit.

Investor Verification Checklist

• Volume Incentive Accounting: Verify the outcome of the SEC review regarding whether volume incentives should be treated as a reduction of revenue or an operating expense.
• Product Liability Exposure: Assess the adequacy of the captive insurance company and accrued liabilities given the inability to insure ephedrine and kava products.
• International Currency Risk: Monitor the impact of foreign currency fluctuations, particularly in Venezuela and Brazil, on future revenue and margins.
• Cost Cutting Execution: Track the realization of the projected $7.0 to $9.0 million in SG&A expense reductions over the next 12-18 months.
• Debt Covenants: Confirm continued compliance with the financial covenants of the $15 million line of credit maturing in July 2004.